National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 9/17/2021 release of VAERS data:

Found 198 cases where Location is U.S., Territories, or Unknown and Vaccine is COVID19 and Manufacturer is MODERNA and Symptom is Guillain-Barre syndrome

Table

   
AgeCountPercent
17-44 Years4623.23%
44-65 Years6733.84%
65-75 Years4723.74%
75+ Years2914.65%
Unknown94.55%
TOTAL198100%



Case Details

This is page 1 out of 20

Result pages: 1 2 3 4 5 6 7 8 9 10   next


VAERS ID: 926703 (history)  
Form: Version 2.0  
Age: 35.0  
Sex: Male  
Location: Oklahoma  
Vaccinated:2020-12-29
Onset:2020-12-29
   Days after vaccination:0
Submitted: 0000-00-00
Entered: 2021-01-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 025J202A / 1 LA / IM

Administered by: Public       Purchased by: ?
Symptoms: Blood test, Guillain-Barre syndrome, Immunoglobulin therapy, Magnetic resonance imaging, Neuralgia, Neurological examination, Paraesthesia
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, 2 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: None
Current Illness: None
Preexisting Conditions: Bradycardia at rest. History of Guillain Barre Syndrome/AIDP in 2010.
Allergies: None
Diagnostic Lab Data: MRI and bloodwork, neuro screening and tests.
CDC Split Type:

Write-up: Guillain Barre syndrome/AIDP event. Paresthesia and nerve pain developed in bilateral legs 4 hours after shot and progressed slowly for 4 days in intensity and area involved. Symptoms progressed distally to superior. On the 5th day symptoms progressed rapidly and involved bilateral legs up to the groin, left arm up to lateral shoulder, and right hand. I went to the hospital and was admitted to start IVIG treatment for Guillain Barre Syndrome/AIDP.


VAERS ID: 951799 (history)  
Form: Version 2.0  
Age: 56.0  
Sex: Female  
Location: Missouri  
Vaccinated:2020-12-29
Onset:2021-01-01
   Days after vaccination:3
Submitted: 0000-00-00
Entered: 2021-01-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / UNK - / -

Administered by: Private       Purchased by: ?
Symptoms: Acute myocardial infarction, Angiogram cerebral, Arteriogram carotid, Back pain, Blood gases, COVID-19 pneumonia, Catheterisation cardiac, Chest X-ray, Chest pain, Computerised tomogram thorax, Critical illness, Depressed level of consciousness, Dyspnoea, Echocardiogram, Electrocardiogram, Endotracheal intubation, Flank pain, Full blood count, Gait disturbance, Guillain-Barre syndrome, Immunoglobulin therapy, Lumbar puncture, Mechanical ventilation, Metabolic function test, Muscular weakness, Nausea, Pain, Respiratory failure, SARS-CoV-2 test positive, Stress cardiomyopathy, Troponin, Vomiting
SMQs:, Rhabdomyolysis/myopathy (broad), Anaphylactic reaction (broad), Acute pancreatitis (broad), Angioedema (broad), Peripheral neuropathy (narrow), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Myocardial infarction (narrow), Anticholinergic syndrome (broad), Retroperitoneal fibrosis (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Embolic and thrombotic events, arterial (narrow), Parkinson-like events (broad), Acute central respiratory depression (narrow), Pulmonary hypertension (broad), Guillain-Barre syndrome (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Cardiomyopathy (narrow), Demyelination (narrow), Other ischaemic heart disease (narrow), Hypotonic-hyporesponsive episode (broad), Generalised convulsive seizures following immunisation (broad), Hypersensitivity (broad), Respiratory failure (narrow), Hypoglycaemia (broad), Infective pneumonia (narrow), Hypokalaemia (broad), Opportunistic infections (broad), Immune-mediated/autoimmune disorders (narrow), COVID-19 (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: atorvastatin (LIPITOR) 10 MG tablet glipiZIDE (GLUCOTROL XL) 10 MG 24 hr tablet losartan (COZAAR) 25 MG tablet metformin (GLUCOPHAGE) 1000 mg tablet pantoprazole (PROTONIX) 40 mg tablets
Current Illness:
Preexisting Conditions: ? Diabetes mellitus ? Hyperlipidemia ? ? Hypertension ? ? Sleep apnea
Allergies: Phenergan Dm
Diagnostic Lab Data: Lumbar puncture 1/15/21 CT Angio Chest: 1/13/2021 CT Angio Head and Neck: 1/15/21 Chest X-ray: 1/15/21 Echocardiogram: 1/13/21 and 1/16/21 ECG: 1/13/21 and 1/16/21 Cardiac catheterization:1/16/21 Blood gases, CBC, Comprehensive metabolic panel, troponin
CDC Split Type:

Write-up: The patient received her first Moderna COVID-19 vaccination on 12/29/2020. However the patient was diagnosed with a positive COVID-19 test on January 4, 2021. Patient complained of nausea, vomiting, back pain, and sharp chest pain. On January 13, the patient presented to the emergency department again with shortness of breath and sharp, stabbing left-sided chest pain radiating to her back and right side. Initial work up ruled out cardiac etiologies. CTA chest demonstrated COVID-19 pneumonia. The patient complained of bilateral lower extremity weakness which had been progressing since her COVID-19 vaccination, per patient report. However, during her hospitalization the patient''s bilateral lower extremity weakness began to accelerate. On the 13th, the patient was able to ambulate to and from the bathroom herself. Then on January 14 the patient required maximum assistance. Neurology was consulted and work up initiated for suspected possible Guillain-Barr? syndrome (GBS) secondary to recent COVID-19 infection. On January 15, 2021, the patient became obtunded and unable to protect airway. She was emergently intubated for acute hypercapnic respiratory failure secondary to GBS. Neurology started GBS treatment with IVIG. Patient also developed NSTEMI and Takotsubo cardiomyopathy. Patient remains critically ill requiring mechanical ventilation.


VAERS ID: 983595 (history)  
Form: Version 2.0  
Age: 50.0  
Sex: Female  
Location: California  
Vaccinated:2021-01-15
Onset:2021-01-16
   Days after vaccination:1
Submitted: 0000-00-00
Entered: 2021-01-28
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 042L20A / 1 LA / IM

Administered by: Other       Purchased by: ?
Symptoms: Guillain-Barre syndrome, Hypoaesthesia, Muscular weakness, Paraesthesia
SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Noninfectious encephalopathy/delirium (broad), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow), Sexual dysfunction (broad)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: Clonidine Hydrochloride - 0.1 mg Simvastatin - 20 mg Losartan Potassium - 25 mg Aspirin 0 81 mg Iron - 130 mg Vitamin C - 1500 mg
Current Illness: Hypertension High cholesterol
Preexisting Conditions: Hypertension High cholesterol
Allergies: None
Diagnostic Lab Data: None
CDC Split Type:

Write-up: Numbness, tingling sensation, weakness of left arm and leg like the Guillain - Barre syndrome (per my primary provider)


VAERS ID: 985773 (history)  
Form: Version 2.0  
Age: 83.0  
Sex: Female  
Location: Minnesota  
Vaccinated:2021-01-15
Onset:2021-01-17
   Days after vaccination:2
Submitted: 0000-00-00
Entered: 2021-01-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 028L20A / 1 AR / IM

Administered by: Unknown       Purchased by: ?
Symptoms: Fall, Gait inability, Guillain-Barre syndrome, Immunoglobulin therapy, Lumbar puncture abnormal, Magnetic resonance imaging abnormal
SMQs:, Peripheral neuropathy (narrow), Anticholinergic syndrome (broad), Dystonia (broad), Guillain-Barre syndrome (narrow), Accidents and injuries (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 9 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies: PCN, caffeine
Diagnostic Lab Data:
CDC Split Type:

Write-up: Resident was hospitalized on 1/17 after having multiple falls and change in condition. Resident returned to facility on 1/20- continued to be unable to ambulate as previous baseline. Son brought resident back to Hospital on 1/21 for further testing. Resident now being treated for Guillan Barre after having lumbar puncture and MRI. She has received IV IG treatments. Resident remains hospitalized.


VAERS ID: 985874 (history)  
Form: Version 2.0  
Age: 76.0  
Sex: Male  
Location: New Mexico  
Vaccinated:2021-01-21
Onset:2021-01-27
   Days after vaccination:6
Submitted: 0000-00-00
Entered: 2021-01-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 030L20A / 1 UN / IM

Administered by: Private       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 3 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Diabetes millitus
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: Gillian Barre Syndrom


VAERS ID: 987080 (history)  
Form: Version 2.0  
Age: 80.0  
Sex: Male  
Location: Pennsylvania  
Vaccinated:2021-01-04
Onset:2021-01-05
   Days after vaccination:1
Submitted: 0000-00-00
Entered: 2021-01-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 011J20A / 1 RA / IM

Administered by: Military       Purchased by: ?
Symptoms: Anti-muscle specific kinase antibody, Asthenia, CSF culture, Dysphagia, Endotracheal intubation, Fungal disease carrier, Guillain-Barre syndrome, Helicobacter test negative, Leukocytosis, Lymphocyte count increased, Magnetic resonance imaging abnormal, Plasmapheresis, Pneumonia, Procalcitonin increased, Protein total, Radiculopathy, Respiratory failure, Sensory loss, Vitamin B12 normal, Vitamin B6 normal
SMQs:, Anaphylactic reaction (broad), Angioedema (broad), Peripheral neuropathy (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Oropharyngeal conditions (excl neoplasms, infections and allergies) (narrow), Acute central respiratory depression (narrow), Guillain-Barre syndrome (narrow), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Gastrointestinal nonspecific symptoms and therapeutic procedures (broad), Demyelination (narrow), Eosinophilic pneumonia (broad), Hypersensitivity (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (narrow), Hypokalaemia (broad), Sepsis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? Yes
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 20 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: prilosec 20 bid flonase 50 mcg nasla spray qhs glipizide 5mg ac breakfast/supper lipitor 10 mg qhs dorzolamide/timolol/ eye drops bid OU latanprost eye drops 1 qhs OU senekot bid prn loratidine 10 mg daily synthroid 125 mcg daily ipratropi
Current Illness: COVID infection 12/8/21
Preexisting Conditions: glaucoma, diabetes, hypothyroidism, hyperlipidemia, elevated PSA, BPH, Lumbar DDD, ED
Allergies: none
Diagnostic Lab Data: Work up at Hospital revealed progressive respiratory failure and pneumonia requiring intubation and progressive ascending weakness and sensory loss without upper motor neuron changes. MRI : nerve root enhancement LP : protein 40, +/- 80 lymphocytes, cultures negative B 12 and B6 normal extensive CSF testing still pending campylobacter and Musk antibodies negative Neurology diagnosed likely AIDP (Guillain-Barre) and an EMG is planned for the near future. His progression and physical exam were classic for GBS Neurology felt the cause of his GBS was likely his covid infection verses his Moderna vaccination He was treated with plasmapheresis.
CDC Split Type:

Write-up: Client developed a mild covid infection 12/8/21 and recovered. He was admitted 12/25 with hypogycemia and mild weakness and sent home He was given his first dose of the Moderna vaccine 1/4/21 at approximately 9AM covid vaccine clinic He developed weakness the next day (1/5) prompting admission to a hospital and then transition to subacute rehabilitation briefly Work up at hospital revealed progressive respiratory failure and pneumonia requiring intubation and progressive ascending weakness and sensory loss without upper motor neuron changes. MRI : nerve root enhancement LP : protein 40, +/- 80 lymphocytes, cultures negative B 12 and B6 normal extensive CSF testing still pending campylobacter and Musk antibodies negative Neurology diagnosed likely AIDP (Guillain-Barre) and an EMG is planned for the near future. Neurology felt the cause of his GBS was likely his covid infection verses his Moderna vaccination He was treated with plasmapheresis. Client received dexamethasone, remdesivir, and zosyn and doxycycline when progressive leukocytosis and procalcitonin elevation was noted. Candida was cultured from tracheal aspirates but felt most likely d/t colonization with an option to treat further if he did not continue to improve. He is now extubated, unable to swallow and has profound weakness and distal sensory loss. He will transition to Acute rehab in the near future. Comorbidities:as described in the above section and... DM2, CKD3, HTN, DJD, BPH ( h/o prostate surgery), h/o Lumbar surgery and hernia repair, GERD, hypothyroidism, hyperlipidemia. Possible etiologies of his AIDP ( GBS) would include his recent covid infection, the Moderna Vaccine, or other undiagnosed infection. He got his flu shot 9/25 ( fluzone sanofi) so this is not likely to be the culprit


VAERS ID: 987105 (history)  
Form: Version 2.0  
Age: 68.0  
Sex: Male  
Location: Oklahoma  
Vaccinated:2021-01-09
Onset:2021-01-19
   Days after vaccination:10
Submitted: 0000-00-00
Entered: 2021-01-29
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 025J20-2A / 1 AR / IM

Administered by: Public       Purchased by: ?
Symptoms: Blood glucose increased, CSF protein increased, Central venous catheterisation, Gait disturbance, Guillain-Barre syndrome, Lumbar puncture abnormal, Magnetic resonance imaging spinal abnormal, Muscular weakness, Plasmapheresis, Spinal cord lipoma, White blood cell count normal
SMQs:, Rhabdomyolysis/myopathy (broad), Peripheral neuropathy (narrow), Hyperglycaemia/new onset diabetes mellitus (narrow), Anticholinergic syndrome (broad), Embolic and thrombotic events, venous (narrow), Parkinson-like events (broad), Guillain-Barre syndrome (narrow), Noninfectious encephalopathy/delirium (broad), Demyelination (narrow), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: 1) ASA 81 mg a day 2) Jardiance 25 mg daily 3)Gabapentin 300 mg TID 4) Insulin 60 units at bedtime 5) Lisinopril 10 mg daily 6) Pravastatin 80 mg daily 7) Janumet XR 50-500 two pills daily
Current Illness: Not applicable
Preexisting Conditions: Diabetes
Allergies: shellfish
Diagnostic Lab Data: 1) Lumbar puncture with elevated CSF protein count of 110 with normal white blood cell count and minimally elevated glucose count 2) MRI of the lumbar spine with lumbar lipoma but no acute process being identified 3) Central line placement and the start of a 5 course plasmapheresis treatment
CDC Split Type:

Write-up: The patient noted weakness starting in the legs on January the 19th, 10 days after receiving the first dose of the vaccine. The weakness progressed to the point that he was able to ambulate only with assistance. He was seen in my neurology clinic on January 28th and his evaluation suggested an ascending, painless weakness of the legs with rapidly progressive symptoms. He was admitted to Hospital on the same day. His evaluation is consistent with Guillain Barre Syndrome and he has been started on plasmapheresis to treat the condition.


VAERS ID: 1002799 (history)  
Form: Version 2.0  
Age: 49.0  
Sex: Male  
Location: Rhode Island  
Vaccinated:2021-01-08
Onset:2021-01-22
   Days after vaccination:14
Submitted: 0000-00-00
Entered: 2021-02-04
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 39K20A / 1 UN / UN

Administered by: Private       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 16 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: This patient was hospitalized and subsequently diagnosed with GBS or AIDP


VAERS ID: 1010981 (history)  
Form: Version 2.0  
Age:   
Sex: Unknown  
Location: Unknown  
Vaccinated:0000-00-00
Onset:2021-01-19
Submitted: 0000-00-00
Entered: 2021-02-08
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA - / 1 - / OT

Administered by: Unknown       Purchased by: ?
Symptoms: Guillain-Barre syndrome
SMQs:, Peripheral neuropathy (narrow), Guillain-Barre syndrome (narrow), Demyelination (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: No adverse event (No reported medical history)
Allergies:
Diagnostic Lab Data:
CDC Split Type: USMODERNATX, INC.MOD20210

Write-up: Potential Guillain-Barre; A spontaneous report was received from a pharmacist concerning an unknown patient who received Moderna''s COVID-19 vaccine and potentially developed Guillain-Barre Syndrome. The patient''s medical history was not provided. No relevant concomitant medications were reported. On an unknown date, the patient received their first of two planned doses of mRNA-1273 intramuscularly for prophylaxis of COVID-19 infection. On 19 Jan 2021, the patient is in the hospital for potential Guillain-Barre Syndrome. No treatment information was provided. Action taken with mRNA-1273 in response to the events was not reported. The outcome of the event, potential Guillain-Barre Syndrome, was unknown/ not reported.; Reporter''s Comments: This case concerns a patient of unknown age and gender, who experienced a serious unexpected event of potential Guillain-Barre Syndrome which required hospitalization. The event occurred on an unspecified date after first dose of mRNA-1273, lot # unknown. Treatment details were not provided. Very limited information regarding this event has been provided at this time. Based on the current available information and temporal association between the use of the product and onset of the event a causal relationship cannot be excluded.


VAERS ID: 1033614 (history)  
Form: Version 2.0  
Age: 42.0  
Sex: Female  
Location: Florida  
Vaccinated:2021-01-15
Onset:2021-01-22
   Days after vaccination:7
Submitted: 0000-00-00
Entered: 2021-02-16
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (MODERNA)) / MODERNA 039K20A / 1 LA / IM

Administered by: Private       Purchased by: ?
Symptoms: Autoimmune demyelinating disease, CSF protein increased, CSF white blood cell count negative, Cauda equina syndrome, Computerised tomogram head normal, Gait disturbance, Guillain-Barre syndrome, Injection site erythema, Injection site reaction, Injection site warmth, Lumbar puncture abnormal, Magnetic resonance imaging brain normal, Magnetic resonance imaging spinal abnormal, Paraesthesia, Peripheral motor neuropathy, Peripheral sensory neuropathy, Plasmapheresis, Protein total increased, Pruritus, White blood cell count decreased
SMQs:, Anaphylactic reaction (broad), Haematopoietic leukopenia (narrow), Peripheral neuropathy (narrow), Systemic lupus erythematosus (broad), Anticholinergic syndrome (broad), Parkinson-like events (broad), Guillain-Barre syndrome (narrow), Extravasation events (injections, infusions and implants) (broad), Optic nerve disorders (broad), Demyelination (narrow), Hypersensitivity (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? Yes
ER Visit? No
ER or Doctor Visit? Yes
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Sjogren''s syndrome, hypothyroidism, anemia
Allergies: Latex, tramadol
Diagnostic Lab Data: CT head without contrast 2/10/21: no acute intracranial abn MRI L-spine 2/12/21: Mild diffuse enhancement of the cauda equina nerve roots, which may be seen with Gillian Barre syndro MRI brain demyelinating disease 2/12/21: No acute intracranial abnormality. No abnormal parenchymal enhancement. No evidence of acute/subacute ischemia LP 2/11/21: cytoalbuminologic dissociation (75 protein, 3 WBC)
CDC Split Type:

Write-up: Patient received first Moderna vaccine on 1/15/2021. Delayed injection site reaction which was warm and erythematous 1 week after vaccination on left arm for which was seen by PCP and prescribed Bactrim for 10 days. On 2/3/21 patient experienced itchiness in hands and feet with pins and needles sensation. Seen by PCP on 2/4/21 and was started on Medrol Dose Pack for pruritis and paresthesias. 2/10/21 presented to ED with progressive sensory motor polyneuropathy and early gait dysfunction. Patient started plasmapharesis treatment for suspected Guillan-Barre Syndrome on 2/11/2021.


Result pages: 1 2 3 4 5 6 7 8 9 10   next

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?TABLE=ON&GROUP1=AGE&EVENTS=ON&SYMPTOMS=Guillain-Barre+syndrome+%2810018767%29&VAX=COVID19&VAXMAN=MODERNA&STATE=NOTFR


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166